SARS Cov 2 Vaccination in Adolescents With Juvenile Idiopathic Arthritis

Recruiting

• Conditions: SARS Cov 2 Vaccination in Adolescents With Juvenile Idiopathic Arthritis

• Registration Number: NCT05547451
• Lead Sponsor: Nantes University Hospital

Brief Summary

Since june 2021, vaccination against the SARS-Cov2 virus is recommanded in France to all children from 12 to 18 years old. In the specific population of teenagers living with juvenile arthritis, the vaccine seems to be safe and well tolerated. It has been shown previously that this population has a vaccine coverage lower than the global population even though few datas are available on this topic The aim of this resarch is to study the vaccination coverage against the SARS-Cov2 virus and more specifically the reasons why adolescents were or were not vaccinated in the population of adolescents with juvenile arthitis followed up in Angers, Nantes and Rennes. For this purpose, a review of the medical record will be done and a questionnaire will be adressed to the family of patients in order to collect informations about the disease, the treatments, the motives or obstacles to vaccination. Secondaries end points are safety of the vaccination, consequences on the juvenile arthritis (such as changes in the medication, flare-up of the illness) and the occurence of covid infection after vaccination.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-09-12
• Study First Submitted QC: 2022-09-16
• Study First Posted: 2022-09-21
• Status Verified: 2024-06
• Study Start: 2024-06-09
• Last Update Submitted: 2024-06-20
• Last Update Posted: 2024-06-21
• Primary Completion: 2025-06-30
• Study Completion: 2025-06-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• Patients from 12 to 18 years old, on January the 1st 2022
• Patients followed up from juvenile arthritis
• Patients followed up in 2021 and 2022

Exclusion Criteria

• Patients under 12 years old.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
SARS Cov2 vaccination coverage of this population and factors influencing the realization of the vaccination.	From june 2021 to December 2022	Percentage of patients vaccinated

Secondary Outcome Measures

Name	Time	Method
Tolerance of the SARS-Cov2 vaccination	From june 2021 to December 2022	Occurrence of any side-effects
SARS-Cov 2 infection after vaccination	From june 2021 to December 2022	Occurrence and severity of the infection
Effect of the SARS Cov2 vaccination on juvenile arthritis	From june 2021 to December 2022	Occurrence of flare up of the illness, modification of treatment

Trial Locations

Locations (1)

CHU de Nantes; 🇫🇷 Nantes, Loire-Atlantique, France